Overview
NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals did not provide an evidence submission.
Last reviewed: 24 February 2021
Next review: We will review this decision if the company decides to make a submission.